• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Inhibrx Biosciences Inc (NQ: INBX )

    13.83 -0.50 (-3.49%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Inhibrx Biosciences Inc

    < Previous 1 2 3 Next >
    Around $2M Bet On Franklin Resources? Check Out These 4 Stocks Executives Are Buying
    Via Benzinga
    Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying
    Via Benzinga
    INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024
    INBX stock results show that Inhibrx beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024
    INBX stock results show that Inhibrx Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Top 4 Health Care Stocks That Are Preparing To Pump This Month
    Via Benzinga
    The NVDA Earnings Effect And What It Means For The Current Market Momentum
    Discover the confluence zone that will make or break the S&P 500 and the preliminary supply (early distribution) you need to be aware of. 
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know
    Via Benzinga
    Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients
    Via Benzinga
    Is The Stock Market Ready To Plunge? The Warning Signs Are Here...
    Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move. 
    Via Talk Markets
    Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx
    The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency. 
    Via Investor's Business Daily
    French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
    Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected... 
    Via Benzinga
    Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
    Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO. 
    Via Benzinga
    $1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying
    Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. 
    Via Benzinga
    Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment. 
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
    On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday. 
    Via Investor's Business Daily
    Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate
    Via Benzinga
    $40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying
    Although US stocks closed slightly lower on Wednesday, there were a few notable insider trades. 
    Via Benzinga
    Stocks Reverse Gains After ADP Report
    Wall Street's rally has come to a screeching halt, as Treasury yields tick higher once again. 
    Via Talk Markets
    Why Is Inhibrx (INBX) Stock Soaring 45% Today?
    Inhibrx received a vote of confidence from the Food and Drug Administration, skyrocketing the largely speculative INBX stock. 
    Via InvestorPlace
    Inhibrx's Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge
    Via Benzinga
    Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
    Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
    Via Benzinga
    S&P 500 Rises 100 Points; Nasdaq Up 3%
    U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday. 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Gainers 
    Via Benzinga
    Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
    Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday. 
    Via Benzinga
    Nasdaq Surges 350 Points; Crude Oil Rises Sharply
    U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday. 
    Via Benzinga
    US Stocks Open Higher As Dow Jumps 550 Points
    U.S. stocks traded higher this morning, with the Dow Jones climbing more than 550 points on Tuesday. 
    Via Benzinga
    Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
    Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday. 
    Via Benzinga
    Recap Of Monday's Biotech Catalysts - End Of the Day Summary
    Via Benzinga
    Inhibrx Secures European Commission Orphan Medicinal Product Designation For Bone Cancer Candidate
    The European Commission (EC) has granted orphan medicinal product designation to Inhibrx’s (NASDAQ: INBX) lead asset INBRX-109 for the treatment of chondrosarcoma. The regulatory grant was based on a... 
    Via Benzinga
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.